Background: Abnormal potassium homeostasis accompanies many secondary forms of hypertension as well as uncommon inherited, monogenic forms of hypertension. We hypothesized that serum potassium may be associated with longitudinal tracking of blood pressure (BP) and development of hypertension.
S
erum potassium is maintained within a narrow range despite wide fluctuations in dietary potassium intake. [1] [2] [3] [4] [5] [6] [7] Secondary 8, 9 and inherited, monogenic 10 -12 forms of hypertension are often accompanied by altered potassium homeostasis resulting in abnormally low 8 -11 or high 12 levels of serum potassium. In a recent report from the Framingham Heart Study, longitudinal systolic blood pressure (BP) was linked to chromosome 17q12 to 21 . 13 Pseudohypoaldosteronism type II, an autosomally dominant form of hypertension and hyperkalemia, has also been linked to this chromosomal interval. 12 Therefore, abnormal potassium homeostasis may accompany development of hypertension, and serum potassium may be associated with longitudinal changes in BP.
We studied the association between serum potassium and longitudinal increase in BP over 4 years of follow up in a community-based sample of nonhypertensive subjects enrolled in the Framingham Heart Study.
Methods

Study Population
The Framingham Heart Study is a prospective epidemiologic cohort study established in 1948 to evaluate potential risk factors for coronary heart disease. The original cohort consisted of 5209 residents of Framingham, MA, aged 28 to 62 years at entry. In 1971, a total of 5124 additional subjects (offspring of original cohort subjects and their spouses) were enrolled in the Framingham Offspring Study. The study design and entry criteria for both cohorts have been detailed elsewhere. 14 Subjects for the present study were members of the offspring cohort who had blood drawn for the measurement of serum potassium at the second offspring examination in 1979 to 1983. Subjects were excluded if they met any of the following criteria: 1) history of hypertension, cardiovascular disease, or valvular heart disease; 2) treatment with medications altering potassium homeostasis (eg, diuretics, potassium supplements, ␤-blockers); 3) serum creatinine Ն180 mol/L (2.0 mg/dL); 4) hemolyzed or missing blood specimen; 5) extreme elevation of serum potassium (Ͼ6.3 mmol/L); or 6) failure to attend the follow-up examination. All examinations and procedures were approved by the Institutional Review Board of Boston University School of Medicine, and all subjects gave informed consent.
Baseline Measurements
Medical histories and physical examinations were obtained for each participant at the baseline examination. Systolic and diastolic BP were measured twice in the left arm of seated participants. The average of the two readings was used for each BP variable. The diagnosis of hypertension was based on a systolic BP of Ն140 mm Hg, a diastolic BP of Ն90 mm Hg, or current use of antihypertensive drugs. 15 Body mass index was calculated as the weight in kilograms divided by the square of the height in meters. Diabetes mellitus was defined on the basis of a fasting blood glucose level of Ն7.8 mmol/L (140 mg/dL) or the use of insulin or an oral hypoglycemic agent. 16 Diagnostic criteria for cardiovascular disease (including myocardial infarction, coronary insufficiency, angina pectoris, stroke, peripheral vascular disease, and congestive heart failure) have been described previously.
14 Serum potassium was measured by flame-emission spectrophotometry. 17 Serum creatinine values were determined by the autoanalyzer technique 18 on blood specimens drawn at the baseline examination.
Outcome Measurements
Progression of BP stage was the principal outcome of interest. At the baseline examination, BP measurements were used to categorize subjects based on the classification scheme defined by the sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure (JNC-VI) 15 : 1) optimal BP (systolic BP Ͻ120 mm Hg and diastolic BP Ͻ80 mm Hg); 2) normal BP (systolic BP 120 to 129 mm Hg or diastolic BP 80 to 84 mm Hg); or 3) high-normal BP (systolic BP 130 to 139 mm Hg or diastolic BP 85 to 89 mm Hg). All subjects had repeat measurement of BP at a follow-up examination approximately 4 years after the baseline examination. Blood pressure measurements at the follow-up examination were used to recategorize subjects into those with 1) optimal BP, 2) normal BP, 3) highnormal BP, or 4) hypertension (systolic BP Ն140 mm Hg, diastolic BP Ն90 mm Hg, or treatment with antihypertensive medications). Progression of BP stage was defined as an increment of one or more JNC-VI BP category between the baseline and follow-up examinations.
Statistical Analysis
Subjects were categorized into sex-specific potassium quartiles. For the primary analysis, sexes were pooled and baseline characteristics were computed for each pooled quartile. Logistic regression models 19 were used to estimate the association of serum potassium quartile and the risk of progression by one or more BP category on followup, adjusting for age, sex, baseline BP category, systolic BP, diastolic BP, smoking, diabetes, body mass index, serum creatinine, and interceding myocardial infarction or congestive heart failure. Subjects in the highest potassium quartile served as the reference group. Results of the regression models were displayed as odds ratios and 95% confidence intervals.
As secondary analyses, multivariable logistic regression models were used to evaluate the association between serum potassium quartile and 1) progression to hypertension, and 2) increase in BP (Ն10 mm Hg increase in systolic BP, Ն5 mm Hg increase in diastolic BP, or treatment with antihypertensive medications) between the baseline and follow-up examinations. Also, the aforementioned analyses were repeated separately by sex. We acknowledge that increased risk for progression of BP stage and progression to hypertension may be confined to individuals with hypokalemia or hyperkalemia. Therefore, we also categorized subjects as having 1) hypokalemia (serum potassium Յ4.0 mmol/L), 2) normokalemia (serum potassium 4.1 to 5.1 mmol/L), or 3) hyperkalemia (serum potassium Ն5.2 mmol/L). We estimated the risk of progression of BP stage and progression to hypertension in subjects with hypokalemia and hyperkalemia compared with subjects with normokalemia, who served as the reference group. Finally, the association between serum potassium and longitudinal change in BP may not be apparent over the relatively short follow-up period of 4 years. Therefore, we repeated the analysis using follow-up information available 8 years after the baseline examination. All statistical analyses were performed using SAS statistical software 20 on a SUN Ultra-Sparc computer (Sun Microsystems Inc., Palo Alto, CA).
Results
Study Sample and Baseline Characteristics
Of 3854 adult subjects attending the baseline examination, 971 had hypertension or were receiving treatment with medications affecting serum potassium levels, and were excluded from the analysis. An additional 99 subjects were excluded because of prevalent cardiovascular disease, valvular heart disease, or serum creatinine Ն180 mol/L (2.0 mg/dL). We further excluded 128 subjects with hemolyzed or missing blood specimens, 10 with extreme elevations of serum potassium (Ͼ6.3 mmol/L), and 288 who failed to attend the follow-up examination, leaving 2358 (1066 men, 1292 women) eligible for the study. Table 1 displays baseline characteristics of the study sample stratified by sex-specific quartiles of serum potassium. In general, serum potassium levels were higher in men than in women. Age and smoking were significantly associated with serum potassium quartile. There were no differences in baseline systolic BP, diastolic BP, or JNC-VI BP category across quartiles of serum potassium. Of subjects attending the baseline examination, 774 were excluded because of untreated hypertension or failure to attend a follow-up examination. No associations were observed between serum potassium and BP parameters after addition of these subjects to the 2358 subjects included in the primary analysis (data not shown).
Serum Potassium and Increase in BP Category
Over 4 years of follow up, 37% of the study sample (457 women, 412 men) progressed by one or more JNC-VI BP category. In each of the lowest three quartiles of serum potassium, fewer subjects progressed by one or more BP category compared with subjects in the highest quartile of serum potassium (Table 2 ). In a logistic regression model adjusting for multiple confounders, risk of BP progression in each of the lowest three quartiles of serum potassium was lower than in subjects in the highest quartile of serum potassium; however, this was only of marginal statistical significance (Table 2) . No association was observed between sex-specific potassium quartile and the risk for BP progression in either men or women after adjusting for multiple confounders (Table 3) . Extending the follow-up period to 8 years did not materially alter the results (data not shown). In the sex-pooled analysis, we had 80% power to detect a 12% change in the odds ratio for BP progression over 4 years of follow-up per quartile of serum potassium.
Serum Potassium and Progression to Hypertension
During the follow-up period, 14% of the study sample (162 women, 175 men) progressed to hypertension. Of these, 240 were untreated at follow-up and 97 were on antihypertensive medications. In each of the lowest three quartiles of serum potassium, fewer subjects progressed to hypertension compared with subjects in the highest quartile of serum potassium (Table 2 ). In a logistic regression model adjusting for multiple confounders, risk of progression to hypertension in each of the lowest three quartiles of serum potassium was lower than in subjects in the highest quartile of serum potassium; however, this difference was not statistically significant (Table 2) . No association was noted between sex-specific potassium quartile and risk for progression to hypertension in men after adjusting for multiple confounders (Table 3 , top). In women, there was a direct association between sex-specific potassium quartile and risk for progression to hypertension that approached statistical significance (Table 3 , bottom). Extending the follow-up period to 8 years did not materially alter the results (data not shown). In the sex-pooled analysis, we had 80% power to detect a 17% change in the odds ratio for progression to hypertension over 4 years of follow-up per quartile of serum potassium.
Serum Potassium and Increase in BP
During the follow-up period, 46% of the study sample had a Ն10 mm Hg increase in systolic BP or a Ն5 mm Hg increment in diastolic BP, or required treatment with antihypertensive medications. After adjusting for multiple confounders, no association was seen between serum potassium and risk for increase in BP between the baseline and follow-up examinations (data not shown). Table 4 displays the risk of progressing up one or more JNC-VI BP category and risk of progression to hypertension in subjects with hypokalemia and hyperkalemia compared with subjects with normokalemia over 4 years of follow-up. After adjustment for multiple confounders, risk for progression of BP stage and progression to hypertension were not significantly different in subjects with hypokalemia nor hyperkalemia compared with those with normokalemia. Similar results were seen after stratifying by sex (Table 5) .
Hypokalemia, Hyperkalemia, and Longitudinal Change in BP
Discussion
A recently reported genome-wide scan in participants in the Framingham Heart Study found strong evidence for linkage of systolic and diastolic BPs to chromosome 17q12 to 21 . 13 This interval of chromosome 17 has also been linked to pseudohypoaldosteronism type II, an autosomally dominant form of hypertension accompanied by hyperkalemia. 12 It is tempting to speculate that a gene in this interval may influence both BP and potassium homeostasis in the general population. We hypothesized that Tables 1 and 2 . * Adjusted for age, sex, baseline BP, diabetes, smoking, body mass index, serum creatinine and interim myocardial infarction or congestive heart failure.
serum potassium may influence longitudinal tracking of BP and progression to hypertension.
In our community-based sample of 2358 subjects without hypertension, serum potassium was not associated with current BP, progression of BP stage, or progression to hypertension over 4 years of follow-up. In subjects with hyperkalemia (serum potassium Ն5.2 mmol/L), there was a nonsignificant increase in risk for both progression of BP stage and progression to hypertension compared with those in subjects with normokalemia.
There are several potential explanations for the lack of association of serum potassium and BP progression in our study. First, several candidate genes other than the pseudohypoaldosteronism type II gene map to chromosome 17q12 to 21, and many of these genes are unrelated to potassium homeostasis. 13 The pseudohypoaldosteronism type II gene mapping to chromosome 17q12 to 21 may contribute little to the longitudinal change in BP in our study sample, explaining why we observed no association between serum potassium and BP progression. Second, serum potassium represents only a small fraction of total body potassium. 21 Significant changes in renal potassium excretion may occur without detectable alterations in serum potassium levels. It is conceivable that more sensitive measures of potassium homeostasis such as urinary potassium excretion, urinary sodium:potassium ratio, or erythrocyte potassium content may be necessary to identify individuals with subclinical abnormalities in potassium metabolism who may be at risk for progression of BP stage and progression to hypertension. Third, BP is a multifactorial trait. Many acquired and inherited forms of hypertension are associated with hypokalemia. Among individuals with primary hyperaldosteronism, total body and serum potassium levels are often reduced because of enhanced urinary excretion of potassium. 22 Other inherited forms of hypertension such as pseuodhypoaldosteronism type II 12 are associated with hyperkalemia. Fourth, inherited disorders of potassium homeostasis may be associated with hypertension, yet compensatory mechanisms may normalize serum potassium values. Many individuals with primary hyperaldosteronism have serum potassium levels within the normal range. 23 Similarly, individuals with inherited, monogenic forms of hypertension such as glucocorticoid-remediable aldosteronism and Liddle's syndrome frequently maintain serum potassium concentrations within the normal range despite abnormal renal potassium handling. 24, 25 Several trials have examined the effects of dietary potassium supplementation on longitudinal changes in BP and progression to hypertension in normotensive subjects.
1,26 -28 Some, 1, 28 but not all, 26, 27 have shown modest reductions in BP among normotensive individuals receiving potassium supplementation. In trials that have reported BP lowering effects of potassium supplementation, changes in serum potassium were small despite large differences in potassium intake between treated and untreated subjects. The comparatively narrow range of dietary potassium intake reported from previous studies of the Framingham Heart Study population 29 suggests that little of the variation in serum potassium in our study population can be attributed to variation in dietary potassium intake. Also, because of the poor correlation between dietary potassium intake and serum potassium levels, our findings cannot be used to draw inferences regarding the association between dietary potassium intake and BP progression.
Our study was conducted in a largely white population and therefore may have limited generalizability to other ethnic populations. Also, the range of serum potassium was narrow in our study sample. Even minor errors in sample preparation or measurement of potassium could result in nondifferential misclassification and would decrease the likelihood of observing a significant association. We attempted to minimize such errors by excluding subjects with either hemolyzed specimens or markedly elevated values of potassium. Release of potassium from platelets during coagulation may artifactually increase serum potassium concentrations; therefore, plasma potassium levels may better reflect the association between potassium and longitudinal BP tracking. 30, 31 Finally, our study may have insufficient statistical power to detect a relatively modest association between serum potassium and BP progression. Additional analyses on larger study samples may be necessary to clarify the association between serum potassium and BP.
In conclusion, in our community-based sample, serum potassium was not associated with current BP, progression of BP stage, or progression to hypertension. This likely reflects the multifactorial nature of human BP variation.
